Focus on FAPI Newsletter – Spring 2024

Dear FAPI Community,

SOFIE is gearing up for an exciting spring season on the FAPI front. Our Gilroy, CA, site, now joins Totowa, NJ, as a production site for GMP grade [¹⁸F]-FAPI-74 for clinical research.  We have begun the process to start production of [¹⁸F]-FAPI-74 at our Romeoville, IL, site, and three additional manufacturing sites for FAPI-74 are planned over the next twelve months.  These are concrete, meaningful steps toward enhancing access to FAPI for our academic and industry partners. Dr. Sharmila Dorbala at Brigham and Women’s Hospital – Harvard Medical School is one such valued partner, with SOFIE recently supporting her study on Imaging Fibroblast Activation in Myocardial Diseases.

I am also pleased to share SOFIE’s support of Avacta’s therapeutic studies targeting FAP. [¹⁸F]-FAPI-74 is serving as a complementary diagnostic in Avacta’s Phase 1 trial for AVA6000, a chemotherapy drug, with the goal of helping better identify FAP expression in the tumor microenvironment.

The annual SNMMI meeting is just around the corner, taking place June 8-11 in Toronto, Canada.  This year we are co-sponsoring with GE HealthCare a satellite symposium, “Driving Molecular Imaging Innovation with ‘FAPI’”, on Sunday, June 9, 6:30-8:30 pm.  Please remember to stop by the SOFIE Booth (1116) to speak to a member of the FAPI team with any questions you may have. Partners, please reach out if you’d like to schedule a meeting at SNMMI. We hope to see you there!

Finally, in SOFIE’s continuing efforts to educate the larger clinical community about FAPI, on May 30, I presented a webinar on the “Current state of FAP Targeting Radioligands”.  If you missed it, it’s available for viewing here. 

As always, thank you for reading our newsletter. We sincerely appreciate your input on how this can be a better resource for the FAPI community.

– Sherly Mosessian, Ph.D., Chief Scientific Officer